Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of the Effect of the Gel on Sensitive Teeth

18. mai 2026 oppdatert av: Lacer S.A.

Evaluation of the Efficacy of a Product for Oral Care in Use Test Under Dentist Control.

The goal of this study is to learn if a tooth gel works to alleviate teeth hypersensitivity in adults. It will also learn about the safety of the product.

The main question it aims to answer is:

• Does the tooth gel help to improve signs of teeth hypersensitivity?

Researchers will compare before and after product use to see if it works to improve teeth sensitivity. Participants will:

  • Use assigned products daily for 14 days
  • Visit the clinic on the established days during 14 days for check-ups and evaluation

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

31

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Barcelona, Spania
        • CLINICA CIURANA Centre Dental

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Healthy female and male subjects (no specific repartition)
  • Aged between 18 years old
  • Subjects with dentine hyperesthesia
  • Have a minimum of two hypersensitive teeth anterior to non-consecutive molars, with cervical erosion/abrasion or gingival recession, and with a grade greater than or equal to 1 on the verbal rating scale (VRS) after tactile simulation, and greater than or equal to 1 on the Schiff cold air sensitive scale at the beginning of the study.
  • Subjects certifying the truthfulness of the personal data disclosed to the investigator
  • Subjects able to understand the language used in the investigation canter and the information given by the investigator
  • Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
  • The pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) should be stable for at least one month without any changes expected or planned during the study
  • Commitment not to change the daily routine or the lifestyle
  • Subjects who have not been recently involved in any other similar study
  • Commitment not to use during the study period other products with the same effect of the tested product
  • Subjects informed about the test procedures and who have signed a consent form.

Exclusion Criteria:

  • Subjects participating or planning to participate in other clinical trials;
  • Subjects deprived of liberty by administrative or judicial decision or under guardianship;
  • Subjects who cannot be contacted in an emergency;
  • Subjects admitted to a health or social center;
  • Subjects planning hospitalization during the study;
  • Subjects who participated in a similar study without respecting an adequate washout period (used any desensitizing agents during the last three months);
  • Subjects who have used anti sensitivity products in the 4 weeks prior to screening;
  • Subjects under pharmacological treatments that the investigator considers incompatible with the requirements of the study;
  • Subjects who have had active caries within 12 months or who are at risk of caries development (multiple dental restorations, crowns with compromised margin) per examiners discretion;
  • Subjects who have shown allergies or sensitivity to any component of the product;
  • Subject breastfeeding, pregnant or not willing to take the necessary precautions to avoid pregnancy during the study (for women of childbearing age).
  • Any tooth surface adjacent to those surfaces under investigation, which in the opinion of the investigator have any other condition that provides symptoms confusing with those of cervical dentin hypersensitivity.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Desensitizing tooth gel
Desensitizing tooth gel was used 3 times a day after meals during 14 days

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in teeth sensitivity to cold air at 14 days.
Tidsramme: From enrolment to the end of use at 14 days.
Change evaluated by VAS score scale from 0 to 3, where 0 means the absence of pain while 3 is the highest pain.
From enrolment to the end of use at 14 days.
Change from Baseline in teeth sensitivity to periodontal probe at 14 days
Tidsramme: From enrolment to the end of use at 14 days.
Change evaluated by VAS score scale: from 0 to 10, where 0 means the absence of pain while 10 is the highest pain
From enrolment to the end of use at 14 days.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. juli 2024

Primær fullføring (Faktiske)

31. juli 2024

Studiet fullført (Faktiske)

31. juli 2024

Datoer for studieregistrering

Først innsendt

12. mai 2026

Først innsendt som oppfylte QC-kriteriene

18. mai 2026

Først lagt ut (Faktiske)

19. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • ES0000257/24

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Only summary of the results to support the publication will be shared. No complete study documents will be shared.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere